Sonnet BioTherapeutics 的收益超出预期，但股价下跌;Chardan 下调目标价，但维持“买入”评级。 Sonnet BioTherapeutics beat earnings forecasts but saw stock fall; Chardan lowered target price but kept "buy" rating.

Sonnet生物治疗学报告季度收入比预期的更好,EPS为1.56美元,殴打分析师预测为11.12美元。 Sonnet BioTherapeutics reported better-than-expected quarterly earnings, with an EPS of ($1.56), beating analyst forecasts of ($11.12). 尽管如此,该公司的股票价格还是下跌了0.02美元,跌至1.54美元。 Despite this, the company's stock price fell by $0.02 to $1.54. Chardan Capital将其价格目标从30.00美元降低至20.00美元, Chardan Capital lowered its price target from $30.00 to $20.00 but maintained a "buy" rating. 索纳特生物治疗法的重点是开发生物药物,利用人体单链抗体碎片进行定向组织交付。 Sonnet BioTherapeutics focuses on developing biologic medicines using human single-chain antibody fragments for targeted tissue delivery.